EULAR 2019: Sun Pharma adds to hopes for new Ilumya indication

14 June 2019
sunpharma-big

Indian drugmaker Sun Pharmaceutical Industries’ (NSE: SUNPHARMA) Ilumya is impressing in a new indication beyond its current plaque psoriasis label, new data presented at EULAR has shown.

The interleukin-23 inhibitor is being studied in a Phase II study in psoriatic arthritis, and an interim analysis has shown that more than 71% of patients treated with Ilumya experienced a 20% improvement in joint and skin symptoms (ACR20), meeting the primary endpoint of the trial.

"We are now exploring a possible Phase III trial for psoriatic arthritis with regulatory authorities"

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology